Advertisement
Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. (KYTX) Stock Competitors & Peer Comparison

See (KYTX) competitors and their performances in Stock Market.

KYTXNASDAQ
HealthcareBiotechnology
$8.44
$0.24(2.93%)
U.S. Market opens in 46h 55m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
KYTX$8.44+2.93%369.6M-2.57-$3.28N/A
VRTX$491.34+2.32%124.7B26.11$18.82N/A
VRNA$106.91+0.11%72.7B-102.80-$1.04N/A
REGN$632.90+2.06%65.2B13.87$45.63+0.58%
ARGX$887.18-0.17%54.9B80.07$11.08N/A
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
RVMDW$8.85+5.73%39.7B-2.13-$4.15N/A
ALNY$291.37-0.61%38.9B52.55$5.55N/A
RVMD$182.08+2.19%38.7B-25.75-$7.07N/A
ONC$279.89+1.65%29.9B62.62$4.47N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

KYTX vs VRTX Comparison June 2026

KYTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KYTX stands at 369.6M. In comparison, VRTX has a market cap of 124.7B. Regarding current trading prices, KYTX is priced at $8.44, while VRTX trades at $491.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KYTX currently has a P/E ratio of -2.57, whereas VRTX's P/E ratio is 26.11. In terms of profitability, KYTX's ROE is -0.82%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, KYTX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for KYTX.Check VRTX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions